首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Bridging the gap: The future of biosimilars regulations. 缩小差距:生物仿制药法规的未来。
IF 4.1 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-06-17 DOI: 10.1080/21645515.2024.2362450
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani

Biosimilar vaccines and immunotherapeutic are innovative approaches in medical research. This commentary addresses the current disparities in regulations of biosimilar vaccines and immunotherapeutic products across different nations. It also navigates the benefits of global regulatory alignment and challenges that may be encountered. The current discrepancies in regulations across different countries, which pose significant challenges for the development and approval of biosimilar vaccines and immunotherapeutic products. These disparities often lead to delayed market access, increased development costs, and hindered innovation. The commentary stresses that such obstacles could be mitigated through harmonized regulations, resulting in faster approvals, reduced healthcare costs, and improved patient outcomes. Moreover, the commentary explores the specific complexities associated with biosimilar vaccines and immunotherapeutic, such as the intricate evaluation of biosimilarity due to their molecular composition and immunogenic properties. In conclusion, the editorial advocates for collaborative efforts to overcome the challenges in achieving global regulatory harmonization for biosimilars. This includes establishing uniform standards, fostering international cooperation among regulatory agencies, and promoting educational initiatives for healthcare providers and regulators. The ultimate goal is to ensure that patients worldwide have timely access to safe, effective, and affordable biosimilar treatments.

生物仿制疫苗和免疫疗法是医学研究的创新方法。本评论探讨了目前不同国家对生物仿制疫苗和免疫治疗产品监管的差异。它还介绍了全球统一监管的好处和可能遇到的挑战。目前不同国家的法规存在差异,这给生物仿制疫苗和免疫治疗产品的开发和审批带来了巨大挑战。这些差异往往导致市场准入延迟、开发成本增加和创新受阻。评注强调,这些障碍可以通过统一法规来缓解,从而加快审批速度、降低医疗成本并改善患者疗效。此外,评论还探讨了与生物仿制疫苗和免疫疗法相关的特殊复杂性,例如由于其分子组成和免疫原性,对生物仿制性的评估错综复杂。最后,社论倡导各方共同努力,克服在实现生物仿制药全球统一监管方面的挑战。这包括建立统一标准、促进监管机构之间的国际合作以及推动针对医疗服务提供者和监管机构的教育活动。最终目标是确保全球患者能够及时获得安全、有效和负担得起的生物仿制药治疗。
{"title":"Bridging the gap: The future of biosimilars regulations.","authors":"Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani","doi":"10.1080/21645515.2024.2362450","DOIUrl":"10.1080/21645515.2024.2362450","url":null,"abstract":"<p><p>Biosimilar vaccines and immunotherapeutic are innovative approaches in medical research. This commentary addresses the current disparities in regulations of biosimilar vaccines and immunotherapeutic products across different nations. It also navigates the benefits of global regulatory alignment and challenges that may be encountered. The current discrepancies in regulations across different countries, which pose significant challenges for the development and approval of biosimilar vaccines and immunotherapeutic products. These disparities often lead to delayed market access, increased development costs, and hindered innovation. The commentary stresses that such obstacles could be mitigated through harmonized regulations, resulting in faster approvals, reduced healthcare costs, and improved patient outcomes. Moreover, the commentary explores the specific complexities associated with biosimilar vaccines and immunotherapeutic, such as the intricate evaluation of biosimilarity due to their molecular composition and immunogenic properties. In conclusion, the editorial advocates for collaborative efforts to overcome the challenges in achieving global regulatory harmonization for biosimilars. This includes establishing uniform standards, fostering international cooperation among regulatory agencies, and promoting educational initiatives for healthcare providers and regulators. The ultimate goal is to ensure that patients worldwide have timely access to safe, effective, and affordable biosimilar treatments.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain. 尼舍韦单抗免疫计划实施前家长对呼吸道合胞病毒的了解:西班牙一个自治区对免疫接种的态度。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-06-10 DOI: 10.1080/21645515.2024.2357439
Matilde Zornoza Moreno, Jaime Jesús Pérez Martín, Mª Cruz Gómez Moreno, Mª Pilar Ros Abellán

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new preventive monoclonal antibody (MAb), nirsevimab, has been launched in the United States, Luxembourg, and France, and was recently approved to be given in a population-based manner throughout Spain. This study aimed to have a first pre-immunization insight into the Spanish parental knowledge about bronchiolitis, RSV, and nirsevimab immunization. Parents in Murcia with children <2 years of age up to the date of September 1, 2023, were selected to complete a questionnaire. The primary endpoint was the parental knowledge about bronchiolitis, RSV, and nirsevimab. A total of 3,217 responses were analyzed. The majority (95.8%) were aware of bronchiolitis. Meanwhile, 46.6% of the respondents knew about RSV, most of them only after the first child's birth. Information about RSV or bronchiolitis was mainly obtained from family members, with only 4.8% reporting having been informed by Health care Professionals (HCPs). Only 11.2% of respondents were aware of nirsevimab. Nonetheless, these were not entirely satisfied with the information received (score of 3.3 out of 5) and shared that HCPs should be the primary source of information. The present survey then highlights the need for better and more efficient educational strategies directed to all parents/legal guardians. It also sheds some light on the different factors that should be considered to improve awareness of RSV immunization to decrease its burden in Spain and beyond.

呼吸道合胞病毒(RSV)是幼儿下呼吸道感染的主要病因,也与大多数支气管炎和肺炎相关的住院治疗有关。一种新的预防性单克隆抗体(MAb)--nirsevimab 已在美国、卢森堡和法国上市,最近又获准在西班牙全国范围内以人群为基础使用。这项研究的目的是在免疫前首次了解西班牙家长对支气管炎、RSV 和 nirsevimab 免疫的认识。穆尔西亚有孩子的家长
{"title":"Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.","authors":"Matilde Zornoza Moreno, Jaime Jesús Pérez Martín, Mª Cruz Gómez Moreno, Mª Pilar Ros Abellán","doi":"10.1080/21645515.2024.2357439","DOIUrl":"10.1080/21645515.2024.2357439","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new preventive monoclonal antibody (MAb), nirsevimab, has been launched in the United States, Luxembourg, and France, and was recently approved to be given in a population-based manner throughout Spain. This study aimed to have a first pre-immunization insight into the Spanish parental knowledge about bronchiolitis, RSV, and nirsevimab immunization. Parents in Murcia with children <2 years of age up to the date of September 1, 2023, were selected to complete a questionnaire. The primary endpoint was the parental knowledge about bronchiolitis, RSV, and nirsevimab. A total of 3,217 responses were analyzed. The majority (95.8%) were aware of bronchiolitis. Meanwhile, 46.6% of the respondents knew about RSV, most of them only after the first child's birth. Information about RSV or bronchiolitis was mainly obtained from family members, with only 4.8% reporting having been informed by Health care Professionals (HCPs). Only 11.2% of respondents were aware of nirsevimab. Nonetheless, these were not entirely satisfied with the information received (score of 3.3 out of 5) and shared that HCPs should be the primary source of information. The present survey then highlights the need for better and more efficient educational strategies directed to all parents/legal guardians. It also sheds some light on the different factors that should be considered to improve awareness of RSV immunization to decrease its burden in Spain and beyond.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An optimized caries model of Streptococcus mutans in rats and its application for evaluating prophylactic vaccines. 优化的大鼠变异链球菌龋齿模型及其在评估预防性疫苗中的应用。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-05-17 DOI: 10.1080/21645515.2024.2345943
Bowen Liu, Min Li, Xian Li, Jingyi Yang, Huimin Yan

Dental caries is a prevalent oral disease that mainly results from Streptococcus mutans. Susceptibility to S. mutans decreased rapidly after weaning in a well-known rat model. However, owing to the lack of time to establish protective immunity ahead of challenge, the weaning rat model is suboptimal for assessing prophylactic vaccines against S. mutans infection. In this study, we found that, in adult rats, S. mutans cultured under air-restricted conditions showed dramatically increased colonization efficacy and accelerated development of dental caries compared with those cultured under air-unrestricted conditions. We propose that S. mutans cultured under air-restricted conditions can be used to develop an optimal caries model, especially for the evaluation of prophylactic efficacy against S. mutans. Therefore, we used the anti-caries vaccine, KFD2-rPAc, to reevaluate the protection against the challenge of S. mutans. In immunized rats, rPAc-specific protective antibodies were robustly elicited by KFD2-rPAc before the challenge. In addition to inhibiting the initial and long-term colonization of S. mutans in vivo, KFD2-rPAc immunization showed an 83% inhibitory efficacy against the development of caries, similar to that previously evaluated in a weaning rat model. These results demonstrate that culturing under air-restricted conditions can promote S. mutans infection in adult rats, thereby helping establish a rat infection model to evaluate the prophylactic efficacy of vaccines and anti-caries drugs.

龋齿是一种常见的口腔疾病,主要由变异链球菌引起。在一种著名的大鼠模型中,对变异链球菌的易感性在断奶后迅速下降。然而,由于断奶后的大鼠缺乏时间来建立保护性免疫,因此断奶后的大鼠模型并不适合用来评估预防性疫苗对变异链球菌感染的效果。在这项研究中,我们发现,与在空气不受限制的条件下培养的大鼠相比,在空气受限制的条件下培养的成年大鼠中,变异杆菌的定植效果显著提高,龋齿的发展速度加快。我们建议,在空气限制条件下培养的变异杆菌可用于开发最佳龋齿模型,尤其是用于评估对变异杆菌的预防效果。因此,我们使用抗龋疫苗 KFD2-rPAc 来重新评估对变异杆菌挑战的保护作用。在免疫大鼠中,KFD2-rPAc能在挑战前激发出强效的rPAc特异性保护抗体。KFD2-rPAc 免疫除了能抑制变异杆菌在体内的初始和长期定植外,对龋齿发展的抑制效果也达到了 83%,与之前在断奶大鼠模型中评估的效果相似。这些结果表明,在空气受限的条件下培养可促进成年大鼠感染变异杆菌,从而有助于建立大鼠感染模型,以评估疫苗和抗龋药物的预防效果。
{"title":"An optimized caries model of <i>Streptococcus mutans</i> in rats and its application for evaluating prophylactic vaccines.","authors":"Bowen Liu, Min Li, Xian Li, Jingyi Yang, Huimin Yan","doi":"10.1080/21645515.2024.2345943","DOIUrl":"10.1080/21645515.2024.2345943","url":null,"abstract":"<p><p>Dental caries is a prevalent oral disease that mainly results from <i>Streptococcus mutans</i>. Susceptibility to <i>S. mutans</i> decreased rapidly after weaning in a well-known rat model. However, owing to the lack of time to establish protective immunity ahead of challenge, the weaning rat model is suboptimal for assessing prophylactic vaccines against <i>S. mutans</i> infection. In this study, we found that, in adult rats, <i>S. mutans</i> cultured under air-restricted conditions showed dramatically increased colonization efficacy and accelerated development of dental caries compared with those cultured under air-unrestricted conditions. We propose that <i>S. mutans</i> cultured under air-restricted conditions can be used to develop an optimal caries model, especially for the evaluation of prophylactic efficacy against <i>S. mutans</i>. Therefore, we used the anti-caries vaccine, KFD2-rPAc, to reevaluate the protection against the challenge of <i>S. mutans</i>. In immunized rats, rPAc-specific protective antibodies were robustly elicited by KFD2-rPAc before the challenge. In addition to inhibiting the initial and long-term colonization of <i>S. mutans in vivo</i>, KFD2-rPAc immunization showed an 83% inhibitory efficacy against the development of caries, similar to that previously evaluated in a weaning rat model. These results demonstrate that culturing under air-restricted conditions can promote <i>S. mutans</i> infection in adult rats, thereby helping establish a rat infection model to evaluate the prophylactic efficacy of vaccines and anti-caries drugs.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk and safety profile in checkpoint inhibitors on non-small-cel lung cancer: A systematic review. 检查点抑制剂治疗非小细胞肺癌的风险和安全性概况:系统综述。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-12-31 Epub Date: 2024-06-27 DOI: 10.1080/21645515.2024.2365771
Sara Maria Majernikova

Treating non-small-cell lung cancer (NSCLC) has gained increased importance in recent years due to the high mortality rate and dismal five-year survival rate. Immune checkpoint inhibitors (ICI) are a promising approach with exceptional outcomes in NSCLC thanks to the antigenic nature of cells. Conversely, immune system over-stimulation with ICI is a double-edged sword that can lead to various negative effects ranging from mild to life-threatening. This review explores current breakthroughs in nanoparticle-based ICI and their limitations. The PubMed, Scopus and Web of Science were examined for relevant publications. Thirty-eight trials (N = 16,781) were included in the analyses. The mixed effects analyses on quantifying the treatment effect contributed significantly to the subgroups within studies for ICI treatment effect. Models confirmed ICI's higher impact on treatment effectivity and the decrease in respondents' mortality compared to conventional treatment regiments. ICI might be used as first-line therapy due to their proven effectiveness and safety profile.

近年来,由于非小细胞肺癌(NSCLC)的高死亡率和令人沮丧的五年生存率,其治疗变得越来越重要。免疫检查点抑制剂(ICI)是一种很有前景的方法,由于细胞的抗原性,它在治疗非小细胞肺癌方面效果显著。相反,免疫系统过度刺激 ICI 是一把双刃剑,可导致轻微到危及生命的各种负面影响。本综述探讨了目前基于纳米粒子的 ICI 取得的突破及其局限性。我们在 PubMed、Scopus 和 Web of Science 上查阅了相关出版物。38项试验(N = 16,781)被纳入分析。量化治疗效果的混合效应分析极大地促进了ICI治疗效果研究中的分组。模型证实,与传统治疗方案相比,ICI 对治疗效果的影响更大,受访者的死亡率也更低。由于 ICI 的有效性和安全性已得到证实,因此可将其用作一线疗法。
{"title":"Risk and safety profile in checkpoint inhibitors on non-small-cel lung cancer: A systematic review.","authors":"Sara Maria Majernikova","doi":"10.1080/21645515.2024.2365771","DOIUrl":"10.1080/21645515.2024.2365771","url":null,"abstract":"<p><p>Treating non-small-cell lung cancer (NSCLC) has gained increased importance in recent years due to the high mortality rate and dismal five-year survival rate. Immune checkpoint inhibitors (ICI) are a promising approach with exceptional outcomes in NSCLC thanks to the antigenic nature of cells. Conversely, immune system over-stimulation with ICI is a double-edged sword that can lead to various negative effects ranging from mild to life-threatening. This review explores current breakthroughs in nanoparticle-based ICI and their limitations. The PubMed, Scopus and Web of Science were examined for relevant publications. Thirty-eight trials (<i>N</i> = 16,781) were included in the analyses. The mixed effects analyses on quantifying the treatment effect contributed significantly to the subgroups within studies for ICI treatment effect. Models confirmed ICI's higher impact on treatment effectivity and the decrease in respondents' mortality compared to conventional treatment regiments. ICI might be used as first-line therapy due to their proven effectiveness and safety profile.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosome may be the next generation of promising cell-free vaccines. 外泌体可能是下一代前景广阔的无细胞疫苗。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-12-31 Epub Date: 2024-05-07 DOI: 10.1080/21645515.2024.2345940
Zelan Dai, Ruiru Cai, Hong Zeng, Hailian Zhu, Youwei Dou, Shibo Sun

Traditional vaccines have limits against some persistent infections and pathogens. The development of novel vaccine technologies is particularly critical for the future. Exosomes play an important role in physiological and pathological processes. Exosomes present many advantages, such as inherent capacity being biocompatible, non-toxic, which make them a more desirable candidate for vaccines. However, research on exosomes are in their infancy and the barriers of low yield, low purity, and weak targeting of exosomes limit their applications in vaccines. Accordingly, further exploration is necessary to improve these problems and subsequently facilitate the functional studies of exosomes. In this study, we reviewed the origin, classification, functions, modifications, separation and purification, and characterization methods of exosomes. Meanwhile, we focused on the role and mechanism of exosomes for cancer and COVID-19 vaccines.

传统疫苗在预防某些顽固性感染和病原体方面存在局限性。开发新型疫苗技术对未来尤为重要。外泌体在生理和病理过程中发挥着重要作用。外泌体具有许多优点,如与生俱来的生物相容性和无毒性,使其成为更理想的疫苗候选物质。然而,对外泌体的研究还处于起步阶段,外泌体产量低、纯度低、靶向性弱等障碍限制了其在疫苗中的应用。因此,有必要进一步探索如何改善这些问题,进而促进外泌体的功能研究。本研究综述了外泌体的起源、分类、功能、修饰、分离纯化和表征方法。同时,我们重点研究了外泌体在癌症和COVID-19疫苗中的作用和机制。
{"title":"Exosome may be the next generation of promising cell-free vaccines.","authors":"Zelan Dai, Ruiru Cai, Hong Zeng, Hailian Zhu, Youwei Dou, Shibo Sun","doi":"10.1080/21645515.2024.2345940","DOIUrl":"10.1080/21645515.2024.2345940","url":null,"abstract":"<p><p>Traditional vaccines have limits against some persistent infections and pathogens. The development of novel vaccine technologies is particularly critical for the future. Exosomes play an important role in physiological and pathological processes. Exosomes present many advantages, such as inherent capacity being biocompatible, non-toxic, which make them a more desirable candidate for vaccines. However, research on exosomes are in their infancy and the barriers of low yield, low purity, and weak targeting of exosomes limit their applications in vaccines. Accordingly, further exploration is necessary to improve these problems and subsequently facilitate the functional studies of exosomes. In this study, we reviewed the origin, classification, functions, modifications, separation and purification, and characterization methods of exosomes. Meanwhile, we focused on the role and mechanism of exosomes for cancer and COVID-19 vaccines.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11086043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare workers' willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo. 刚果民主共和国医护人员接受 COVID-19 强化剂量的意愿及相关因素。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-05-23 DOI: 10.1080/21645515.2024.2357214
Bertin Mindje Kolomba, Francois Kalenga Luhembwe, Deca Blood Banza Ndala, Pacifique Kanku Wa Ilunga, Paul Ciamala Mukendi, Amide Ngongo Kitenge, John Ngoy Lumbule, Elie Kilolo Ngoy, Antoine Umba Ilunga, Judith Mbidi Miema, Christelle Kalikat Mwavita, Guillaume Ngoy Mwamba, Aime Cikomola Wa Bene, Audry Mulumba Wakamba, Alain Ngashi Ngongo, Michel Kabamba Nzaji

The COVID-19 booster dose is considered an important adjunct for the control of the COVID-19 pandemic due to reports of reduced immunity in fully vaccinated individuals. The aims of this study were to assess healthcare workers' intention to receive the booster dose of COVID-19 vaccine and to identify predictive factors among healthcare workers. A cross-sectional study was conducted among healthcare workers selected in two provinces, Kasai Oriental, and Haut-Lomami. Data were collected using a questionnaire administered through structured face-to-face interviews, with respondents using a pre-tested questionnaire set up on the Open Data Kit (ODK Collect). All data were analyzed using SPSS v26.0 (IBM Corporation, Armonk, NY, USA). Vaccination coverage for COVID-19, considering declarations by health workers, is around 85.9% for the province of Kasai Oriental and 85.8% for Haut-Lomami. A total of 975 responses were collected, 71.4% of health workers at Kasai Oriental and 66.4% from Haut-Lomami declared a definite willingness to receive a COVID-19 vaccine booster. The duration of protection was the main reason for accepting a booster COVID-19 dose for 64.6% of the respondents. Logistic regression analysis showed that having chronic diseases (aOR = 2.95 [1.65-5.28]), having already received one of the COVID-19 vaccines (aOR = 2.72 [1.43-5. 19]); the belief that only high-risk individuals, such as healthcare professionals and elderly people suffering from other illnesses, needed a booster dose (aOR = 1.75 [1.10-2.81]). Considering the burden of COVID-19, a high acceptance rate for booster doses could be essential to control the pandemic. Our results are novel and could help policymakers design and implement specific COVID-19 vaccination programs to reduce reluctance to seek booster vaccination.

由于有报道称完全接种过疫苗的人免疫力下降,COVID-19加强剂被认为是控制COVID-19大流行的重要辅助手段。本研究旨在评估医护人员接种 COVID-19 加强剂疫苗的意愿,并确定医护人员的预测因素。研究在东开赛省和上洛马米省两个省份的医护人员中进行了横断面研究。通过结构化面对面访谈的方式进行问卷调查,受访者使用在开放数据工具包(ODK Collect)上设置的预检问卷收集数据。所有数据均使用 SPSS v26.0(IBM 公司,美国纽约阿蒙克)进行分析。根据卫生工作者的申报,COVID-19 疫苗接种覆盖率在东开赛省约为 85.9%,在上洛马米省约为 85.8%。共收集到 975 份答复,71.4% 的东开赛省卫生工作者和 66.4% 的上洛马米省卫生工作者明确表示愿意接种 COVID-19 强化疫苗。64.6%的受访者接受 COVID-19 强化接种的主要原因是保护期。逻辑回归分析表明,患有慢性疾病(aOR = 2.95 [1.65-5.28])、已经接种过一种 COVID-19 疫苗(aOR = 2.72 [1.43-5.19])、认为只有高危人群(如医护人员和患有其他疾病的老人)才需要接种加强剂(aOR = 1.75 [1.10-2.81])。考虑到 COVID-19 带来的负担,较高的加强剂量接受率对于控制大流行至关重要。我们的研究结果很新颖,可以帮助政策制定者设计和实施特定的COVID-19疫苗接种计划,以减少不愿意接种强化疫苗的情况。
{"title":"Healthcare workers' willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo.","authors":"Bertin Mindje Kolomba, Francois Kalenga Luhembwe, Deca Blood Banza Ndala, Pacifique Kanku Wa Ilunga, Paul Ciamala Mukendi, Amide Ngongo Kitenge, John Ngoy Lumbule, Elie Kilolo Ngoy, Antoine Umba Ilunga, Judith Mbidi Miema, Christelle Kalikat Mwavita, Guillaume Ngoy Mwamba, Aime Cikomola Wa Bene, Audry Mulumba Wakamba, Alain Ngashi Ngongo, Michel Kabamba Nzaji","doi":"10.1080/21645515.2024.2357214","DOIUrl":"10.1080/21645515.2024.2357214","url":null,"abstract":"<p><p>The COVID-19 booster dose is considered an important adjunct for the control of the COVID-19 pandemic due to reports of reduced immunity in fully vaccinated individuals. The aims of this study were to assess healthcare workers' intention to receive the booster dose of COVID-19 vaccine and to identify predictive factors among healthcare workers. A cross-sectional study was conducted among healthcare workers selected in two provinces, Kasai Oriental, and Haut-Lomami. Data were collected using a questionnaire administered through structured face-to-face interviews, with respondents using a pre-tested questionnaire set up on the Open Data Kit (ODK Collect). All data were analyzed using SPSS v26.0 (IBM Corporation, Armonk, NY, USA). Vaccination coverage for COVID-19, considering declarations by health workers, is around 85.9% for the province of Kasai Oriental and 85.8% for Haut-Lomami. A total of 975 responses were collected, 71.4% of health workers at Kasai Oriental and 66.4% from Haut-Lomami declared a definite willingness to receive a COVID-19 vaccine booster. The duration of protection was the main reason for accepting a booster COVID-19 dose for 64.6% of the respondents. Logistic regression analysis showed that having chronic diseases (aOR = 2.95 [1.65-5.28]), having already received one of the COVID-19 vaccines (aOR = 2.72 [1.43-5. 19]); the belief that only high-risk individuals, such as healthcare professionals and elderly people suffering from other illnesses, needed a booster dose (aOR = 1.75 [1.10-2.81]). Considering the burden of COVID-19, a high acceptance rate for booster doses could be essential to control the pandemic. Our results are novel and could help policymakers design and implement specific COVID-19 vaccination programs to reduce reluctance to seek booster vaccination.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits, challenges, and strategies related to using presumptive recommendations for HPV vaccination: A qualitative study with rural and non-rural-serving primary care professionals. 与使用 HPV 疫苗接种推定建议相关的益处、挑战和策略:一项针对农村和非农村初级保健专业人员的定性研究。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-12-31 Epub Date: 2024-05-06 DOI: 10.1080/21645515.2024.2347018
Olufeyisayo O Odebunmi, Lisa P Spees, Caitlin B Biddell, Tatenda Yemeke, Juan Yanguela, Colleen Higgins, Melissa B Gilkey, Sachiko Ozawa, Stephanie B Wheeler

HPV vaccination coverage remains far below the national target of 80% among US adolescents, particularly in rural areas, which have vaccine uptake rates that are 10% points lower than non-rural areas on average. Primary care professionals (PCPs) can increase coverage by using presumptive recommendations to introduce HPV vaccination in a way that assumes parents want to vaccinate. Through semi-structured interviews, we explored PCPs' experiences and perceptions of using presumptive recommendations in rural- and non-rural-serving primary care clinics in North Carolina. Thematic analysis revealed that most PCPs in rural and non-rural contexts used presumptive recommendations and felt the strategy was an effective and concise way to introduce the topic of HPV vaccination to parents. At the same time, some PCPs raised concerns about presumptive recommendations potentially straining relationships with certain parents, including those who had previously declined HPV vaccine or who distrust medical authority due to their past experiences with the healthcare system. PCPs dealt with these challenges by using a more open-ended approach when introducing HPV vaccination to parents. In conclusion, our findings suggest that PCPs in both rural and non-rural settings see value in using presumptive recommendations to introduce HPV vaccination, but to adequately address concerns and ensure increased HPV vaccine uptake, PCPs can use simple and culturally sensitive language to ensure fully informed consent and to maintain parental trust. And to further strengthen HPV vaccine discussions, PCPs can utilize other effective HPV communication techniques, like the Announcement Approach, in discussing HPV vaccinations with hesitant parents.

在美国青少年中,HPV 疫苗接种率仍远低于 80% 的国家目标,尤其是在农村地区,疫苗接种率比非农村地区平均低 10%。初级保健专业人员(PCPs)可以通过使用推定建议的方式提高疫苗接种率,这种方式假定家长愿意接种疫苗。通过半结构式访谈,我们探讨了北卡罗来纳州农村和非农村初级保健诊所的初级保健医生使用推定建议的经验和看法。主题分析表明,农村和非农村地区的大多数初级保健医生都使用了推定建议,并认为该策略是向家长介绍 HPV 疫苗接种主题的一种有效而简洁的方式。与此同时,一些初级保健医生担心推定建议可能会使他们与某些家长的关系变得紧张,其中包括那些之前拒绝接受 HPV 疫苗接种的家长,或者那些由于过去在医疗系统中的经历而不信任医疗权威的家长。为了应对这些挑战,初级保健医生在向家长介绍 HPV 疫苗接种时采用了更加开放的方式。总之,我们的研究结果表明,农村和非农村地区的初级保健医生都认为使用推定建议来介绍 HPV 疫苗接种很有价值,但为了充分消除顾虑并确保提高 HPV 疫苗的接种率,初级保健医生可以使用简单且具有文化敏感性的语言来确保完全知情同意并保持家长的信任。为了进一步加强对 HPV 疫苗的讨论,初级保健医生在与犹豫不决的家长讨论 HPV 疫苗接种问题时,可以利用其他有效的 HPV 沟通技巧,如 "公告法"。
{"title":"Benefits, challenges, and strategies related to using presumptive recommendations for HPV vaccination: A qualitative study with rural and non-rural-serving primary care professionals.","authors":"Olufeyisayo O Odebunmi, Lisa P Spees, Caitlin B Biddell, Tatenda Yemeke, Juan Yanguela, Colleen Higgins, Melissa B Gilkey, Sachiko Ozawa, Stephanie B Wheeler","doi":"10.1080/21645515.2024.2347018","DOIUrl":"10.1080/21645515.2024.2347018","url":null,"abstract":"<p><p>HPV vaccination coverage remains far below the national target of 80% among US adolescents, particularly in rural areas, which have vaccine uptake rates that are 10% points lower than non-rural areas on average. Primary care professionals (PCPs) can increase coverage by using presumptive recommendations to introduce HPV vaccination in a way that assumes parents want to vaccinate. Through semi-structured interviews, we explored PCPs' experiences and perceptions of using presumptive recommendations in rural- and non-rural-serving primary care clinics in North Carolina. Thematic analysis revealed that most PCPs in rural and non-rural contexts used presumptive recommendations and felt the strategy was an effective and concise way to introduce the topic of HPV vaccination to parents. At the same time, some PCPs raised concerns about presumptive recommendations potentially straining relationships with certain parents, including those who had previously declined HPV vaccine or who distrust medical authority due to their past experiences with the healthcare system. PCPs dealt with these challenges by using a more open-ended approach when introducing HPV vaccination to parents. In conclusion, our findings suggest that PCPs in both rural and non-rural settings see value in using presumptive recommendations to introduce HPV vaccination, but to adequately address concerns and ensure increased HPV vaccine uptake, PCPs can use simple and culturally sensitive language to ensure fully informed consent and to maintain parental trust. And to further strengthen HPV vaccine discussions, PCPs can utilize other effective HPV communication techniques, like the Announcement Approach, in discussing HPV vaccinations with hesitant parents.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11085946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs. 国家和地区免疫计划实施系统中人类乳头瘤病毒疫苗接种策略的系统性文献综述。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-12-31 Epub Date: 2024-02-27 DOI: 10.1080/21645515.2024.2319426
Marisa Felsher, Meheret Shumet, Cristinela Velicu, Ya-Ting Chen, Kinga Nowicka, Magdalena Marzec, Gabriela Skowronek, Izabela Pieniążek

The uptake of human papillomavirus (HPV) vaccine remains suboptimal despite being a part of routine vaccination within national immunization program(s). This indicates probable challenges with the implementation of HPV immunization program(s) in various countries. The objective of this systematic literature review (SLR) was to identify implementation strategies for HPV vaccination within national and regional immunization programs worldwide with an aim to provide guidance for countries targeting to increase their HPV vaccine coverage rate (VCR). A comprehensive literature search was conducted across Medline and Embase and included articles published between January 2012 and January 2022. Of the 2,549 articles retrieved, 168 met inclusion criteria and were included in the review. Strategies shown to improve HPV vaccination uptake in the reviewed literature include campaigns to increase community awareness and knowledge of HPV, health care provider trainings, integrating HPV vaccination within school settings, coordinated efforts via multi-sectoral partnerships, and vaccination reminder and recall systems. Findings may help national authorities understand key considerations for HPV vaccination when designing and implementing programs aiming to increase HPV VCR in adolescents.

尽管人类乳头瘤病毒 (HPV) 疫苗是国家免疫计划中常规疫苗接种的一部分,但其接种率仍然不尽如人意。这表明各国在实施 HPV 免疫接种计划时可能面临挑战。本系统性文献综述(SLR)的目的是确定全球国家和地区免疫接种计划中 HPV 疫苗接种的实施策略,从而为各国提高 HPV 疫苗接种覆盖率(VCR)提供指导。该研究对 Medline 和 Embase 进行了全面的文献检索,包括 2012 年 1 月至 2022 年 1 月间发表的文章。在检索到的 2,549 篇文章中,有 168 篇符合纳入标准并被纳入综述。综述文献中显示的提高 HPV 疫苗接种率的策略包括提高社区对 HPV 的认识和了解的活动、医疗保健提供者培训、将 HPV 疫苗接种纳入学校环境、通过多部门合作开展协调工作以及疫苗接种提醒和召回系统。研究结果可帮助国家当局在设计和实施旨在提高青少年HPV疫苗接种率的计划时了解HPV疫苗接种的主要注意事项。
{"title":"A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs.","authors":"Marisa Felsher, Meheret Shumet, Cristinela Velicu, Ya-Ting Chen, Kinga Nowicka, Magdalena Marzec, Gabriela Skowronek, Izabela Pieniążek","doi":"10.1080/21645515.2024.2319426","DOIUrl":"10.1080/21645515.2024.2319426","url":null,"abstract":"<p><p>The uptake of human papillomavirus (HPV) vaccine remains suboptimal despite being a part of routine vaccination within national immunization program(s). This indicates probable challenges with the implementation of HPV immunization program(s) in various countries. The objective of this systematic literature review (SLR) was to identify implementation strategies for HPV vaccination within national and regional immunization programs worldwide with an aim to provide guidance for countries targeting to increase their HPV vaccine coverage rate (VCR). A comprehensive literature search was conducted across Medline and Embase and included articles published between January 2012 and January 2022. Of the 2,549 articles retrieved, 168 met inclusion criteria and were included in the review. Strategies shown to improve HPV vaccination uptake in the reviewed literature include campaigns to increase community awareness and knowledge of HPV, health care provider trainings, integrating HPV vaccination within school settings, coordinated efforts via multi-sectoral partnerships, and vaccination reminder and recall systems. Findings may help national authorities understand key considerations for HPV vaccination when designing and implementing programs aiming to increase HPV VCR in adolescents.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139974126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to "A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023: A correspondence". 对 "2012 年至 2023 年 CAR-T 细胞治疗血液恶性肿瘤的文献计量和知识图谱研究:通信"。
IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-12-31 Epub Date: 2024-08-07 DOI: 10.1080/21645515.2024.2386225
Huimin Li, Qing Huang, Yuan Zhang
{"title":"Response to \"A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023: A correspondence\".","authors":"Huimin Li, Qing Huang, Yuan Zhang","doi":"10.1080/21645515.2024.2386225","DOIUrl":"https://doi.org/10.1080/21645515.2024.2386225","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human vaccines and immunotherapeutics: News December 2023. 人类疫苗和免疫疗法:2023 年 12 月新闻。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-01-17 DOI: 10.1080/21645515.2024.2305025
Ronald Ellis, Adam Weiss
{"title":"Human vaccines and immunotherapeutics: News December 2023.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2024.2305025","DOIUrl":"10.1080/21645515.2024.2305025","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1